Find Funding Opportunities

Notice Intent Publish Funding Opportunity Announcement Blueprint Neurotherapeutics Network BPN): Small Molecule Drug Discovery Development Disorders the Nervous System U44 Clinical Trial Optional) Notice Number: NOT-NS-20-032 Key Dates Release Date: January 06, 2020 Estimated Publication Date Funding Opportunity Announcement: February 08, 2020 First Estimated Application Due Date: August 11, 2020 Earliest Estimated Award Date: February 16, 2021 Earliest Estimated Start Date: April 01, 2021 Related Announcements None Issued National Institute Neurological Disorders Stroke NINDS) Purpose NIH announces intention reissue PAR-18-541 SBIR-eligible small businesses seeking support the Blueprint Neurotherapeutics Network BPN). Applicants encouraged utilize customized set contract resources, consultants the Blueprint Neurotherapeutics Network BPN) help advance neuroscience-focused drug discovery development projects the clinic. Notice provided allow potential applicants sufficient time develop meaningful collaborations responsive projects. FOA utilize U44 activity code. Details the planned FOA provided below. FOA expected be published February 2020 an expected application due date August 2020. Research Initiative Details facilitate drug discovery development the neuroscience community, NIH Blueprint Neuroscience Research http://neuroscienceblueprint.nih.gov/) established Blueprint Neurotherapeutics Network BPN), collection contract service providers consultants extensive industry experience the areas pharmacology, medicinal chemistry, pharmacokinetics, toxicology, GMP synthesis, formulation development, Phase clinical safety testing. list consultants contract service providers be viewed http://neuroscienceblueprint.nih.gov/bpdrugs/bpn.htm. reissued Funding Opportunity Announcement FOA) encourage applications SBIR-eligible small businesses seeking funding through Fast-Track phased U44 cooperative agreement mechanism help advance drug discovery development projects the clinic. Applicants be encouraged build customized utilization BPN services their applications. be eligible the BPN, applicant must well-validated bioactive compound(s) hand; BPN does support screening hit compounds. Projects enter BPN during Discovery Development may seek support through phase I/first-in-human testing. Discovery involves iterative medicinal chemistry improve potency ADMET properties compounds, toward goal identifying clinical candidate. During Development, clinical candidate undergoes preclinical toxicology testing required an IND manufacturing, ultimately advancing phase I/first-in-human testing. BPN Development activities include chemical manufacturing controls CMC), formulation development, toxicology studies, regulatory support, phase I/first-in-human testing. NIH assemble customized Lead Development Team each project accepted the program. Lead Development Team typically be co-chaired the Program Director/Principal Investigator PD/PI) a consultant extensive industry expertise identified supported the NIH. Lead Development Team also include members the PD/PI's team, NIH-hired consultants additional expertise, NIH staff. Lead Development Team plan coordinate work supported the cooperative agreement award conducted BPN contractors. Discovery projects begin a U44 Phase award up two years. first 6-12 months be used complete any studies required meet Discovery Development entry criteria to engage Lead Development Team establishing detailed research plan, go/no-go milestones, all subsequent work. Applicants strongly encouraged consult NIH program staff plans an application being developed. Consultations include conference calls NIH program staff webinars. Early contact provides opportunity NIH program staff discuss program scope, entry criteria, goals, to provide information guidance how develop competitive application. It's recommended applicants contact NIH staff least 8 weeks before receipt date. additional information the BPN, please http://neuroscienceblueprint.nih.gov/bpdrugs/index.htm Funding Information Estimated Total Funding Expected Number Awards TBD Estimated Award Ceiling Primary CFDA Numbers TBD nbsp; Anticipated Eligible Organizations Public/State Controlled Institution Higher Education Private Institution Higher Education Nonprofit 501(c)(3) IRS Status than Institution Higher Education) Small Business For-Profit Organization than Small Business) State Government Indian/Native American Tribal Government Federally Recognized) County governments Independent school districts Public housing authorities/Indian housing authorities Indian/Native American Tribally Designated Organization Native American tribal organizations than Federally recognized tribal governments) U.S. Territory Possession Indian/Native American Tribal Government than Federally Recognized) Non-domestic non-U.S.) Entity Foreign Organization) Regional Organization Applications not being solicited this time. Inquiries Please direct inquiries to: Charles Cywin, PhD National Institute Neurological Disorders Stroke NINDS) 301-496-1779 Email: cywincl@ninds.nih.gov

Notice Intent Publish Funding Opportunity Announcement Blueprint Neurotherapeutics Network BPN): Small Molecule Drug Discovery Development Disorders the Nervous System UG3/UH3 Clinical Trial Optional) Notice Number: NOT-NS-20-033 Key Dates Release Date: January 06, 2020 Estimated Publication Date Funding Opportunity Announcement: February 11, 2020 First Estimated Application Due Date: August 08, 2020 Earliest Estimated Award Date: February 01, 2021 Earliest Estimated Start Date: April 01, 2021 Related Announcements None Issued National Institute Neurological Disorders Stroke NINDS) Purpose NIH announces intention reissue PAR-18-546 investigators seeking support the Blueprint Neurotherapeutics BPN) Network. Applicants be encouraged utilize customized set contract resources, consultants the BPN Network help advance neuroscience-focused drug discovery development projects the clinic. Notice provided allow potential applicants sufficient time develop meaningful collaborations responsive projects. FOA utilize UG3/UH3 activity code. Details the planned FOA provided below. FOA expected be published February 2020 an expected application due date August 2020. Research Initiative Details facilitate drug discovery development the neuroscience community, NIH Blueprint Neuroscience Research http://neuroscienceblueprint.nih.gov/) established Blueprint Neurotherapeutics BPN) Network, collection contract service providers consultants extensive industry experience the areas pharmacology, medicinal chemistry, pharmacokinetics, toxicology, GMP synthesis, formulation development, Phase clinical safety testing. list consultants contract service providers be viewed http://neuroscienceblueprint.nih.gov/bpdrugs/bpn.htm. planned reissue Funding Opportunity Announcement FOA) encourage applications investigators seeking funding through UG3/UH3 phased cooperative agreement mechanism help advance drug discovery development projects the clinic. Applicants be encouraged build customized utilization BPN services their applications. be eligible the BPN, applicant must well-validated bioactive compound(s) hand; BPN does support screening hit compounds. Projects enter BPN during Discovery Development may seek support through phase I/first-in-human testing. Discovery involves iterative medicinal chemistry improve potency ADMET properties compounds, toward goal identifying clinical candidate. During Development, clinical candidate undergoes preclinical toxicology testing required an IND manufacturing, ultimately advancing phase I/first-in-human testing. BPN Development activities include chemical manufacturing controls CMC), formulation development, toxicology studies, regulatory support, phase I/first-in-human testing. NIH assemble customized Lead Development Team each project accepted the program. Lead Development Team typically be co-chaired the Program Director/Principal Investigator PD/PI) a consultant extensive industry expertise identified supported the NIH. Lead Development Team also include members the PD/PI's team, NIH-hired consultants additional expertise, NIH staff. Lead Development Team plan coordinate work supported the cooperative agreement award conducted BPN contractors. projects enter BPN begin a preparatory phase UG3) up one year, can used complete any studies required meet Discovery Development entry criteria to engage Lead Development Team establishing detailed research plan, go/no-go milestones, all subsequent work. Applicants strongly encouraged consult NIH program staff plans an application being developed. Consultations include conference calls NIH program staff webinars. Early contact provides opportunity NIH program staff discuss program scope, entry criteria, goals, to provide information guidance how develop competitive application. It's recommended applicants contact NIH staff least 8 weeks before receipt date. additional information the BPN, please http://neuroscienceblueprint.nih.gov/bpdrugs/index.htm Funding Information Estimated Total Funding Expected Number Awards TBD Estimated Award Ceiling Primary CFDA Numbers TBD Anticipated Eligible Organizations Public/State Controlled Institution Higher Education Private Institution Higher Education Nonprofit 501(c)(3) IRS Status than Institution Higher Education) Small Business For-Profit Organization than Small Business) State Government Indian/Native American Tribal Government Federally Recognized) County governments Independent school districts Public housing authorities/Indian housing authorities Indian/Native American Tribally Designated Organization Native American tribal organizations than Federally recognized tribal governments) U.S. Territory Possession Indian/Native American Tribal Government than Federally Recognized) Non-domestic non-U.S.) Entity Foreign Organization) Regional Organization Applications not being solicited this time. Inquiries Please direct inquiries to: Charles Cywin, PhD National Institute Neurological Disorders Stroke NINDS) 301-496-1779 Email: cywincl@ninds.nih.gov

Addition SBIR Direct-to-Phase II Program NINDS RFA-NS-18-012, Translational Neural Devices U44 Clinical Trial Required)" Notice Number: NOT-NS-20-034 Key Dates Release Date: January 6, 2020 Related Announcements RFA-NS-18-012 Issued National Institute Neurological Disorders Stroke NINDS) Purpose Section 5106 the SBIR/STTR Reauthorization Act 2011 authorized NIH ‘issue Phase II award a small business concern did receive Phase award that research/research & development'. phase flexbility' called ‘Direct-to-Phase II’ SBIR award. original authority this provision expired 9/30/2017. Recent legislation P.L. 115-232 re-instated SBIR Direct Phase II provision through Fiscal Year 2022. SBIR Direct-to-Phase II authority not available the STTR program not available the CDC, FDA, ACL SBIR progams. such, NIH re-implementing SBIR Direct-to-Phase II program. prior program specific SBIR Direct-to-Phase II funding opportunity announcements FOAs). transition FORMS-E earlier year allows NIH track SBIR Direct-to-Phase II applications the Application level, there a new check-box the SBIR/STTR Information Form Direct Phase II. a result this, NIH does need issue separate SBIR Direct-to-Phase II FOAs before, can offer Direct-to-Phase II an allowable Application Type any SBIR FOA. NINDS therefore amending RFA-NS-18-012 allow SBIR Direct-to-Phase II submissions NIH strongly encourages small businesses contact appropriate Institute Center early their application planning process ensure technology of priority the Institute/Center following sections RFA-NS-18-012 changed follows: Part 2, Section II. Award Information Currently Reads: Application Types Allowed New Fast-Track) Resubmission Fast-Track) Revision Fast-Track) OER Glossary the SF424 R&R) SBIR/STTR Application Guide provide details these application types. Modified Read: Application Types Allowed New Fast-Track) New Phase II - Direct Phase II) Resubmission Direct Phase II, Fast-Track) Revision Direct Phase II, Fast-Track) OER Glossary the SF424 R&R) SBIR/STTR Application Guide provide details these application types. other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Emily Caporello, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1779 Email: Emily.caporello@nih.gov Nick Langhals, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1779 Email: nick.langhals@nih.gov

Notice NINDS Participation PA-18-917 Developing Therapeutic Potential the Endocannabinoid System Pain Treatment R01 - Clinical Trial Optional)" Notice Number: NOT-NS-20-036 Key Dates Release Date: January 03, 2020 Related Announcements PA-18-917 Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this Notice to inform potential applicants the National Institute Neurological Disorders Stroke NINDS) participate, effective immediately, PA-18-917 Developing Therapeutic Potential the Endocannabinoid System Pain Treatment R01 - Clinical Trial Optional)". notice be effective the February 5, 2020 standard receipt date subsequent due dates. following italicized changes made indicate participation NINDS this FOA. Currently Reads: Part 1. Overview Information Components Participating Organizations National Institute Drug Abuse NIDA) National Cancer Institute NCI)) National Center Complementary Integrative Health NCCIH) National Institute Alcohol Abuse Alcoholism NIAAA) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Aging NIA) Catalog Federal Domestic Assistance CFDA) Number(s) 93.279, 93.393, 93.213, 93.273, 93.865, 93.866 Part 2. Full Text Announcement Section I. Funding Opportunity Description addition the topics listed above, additional specific areas interest some the participating ICs outlined below. Applicants encouraged contact participating IC's Scientific/Research contact discuss submission gauge interest the participating institute. NIDA: Examine role various combinations potencies the main cannabinoids THC CBD) their effects modulating endocannabinoid system pain perception analgesia; effects long-term endocannabinoid system therapies addiction liability. NCI: role cannabinoids the endocannabinoid system the treatment tumor-related pain conditions, such metastatic bone pain, painful conditions arising the treatment cancer, such chemotherapy induced peripheral neuropathy, aromatase inhibitor arthralgias, radiation induced stomatitis. NCCIH: role naturally occurring phytocannabinoids their derivatives either alone in conjunction other complementary approaches e.g. natural products, mind-body programs) modulating biological neural systems associated pain perception analgesia relevant model organisms human subjects well the mechanisms underlying cannabinoid analgesic anti-inflammatory properties. NCCIH not fund research proposing efficacy effectiveness clinical trials through FOA please NCCIH Clinical Trial Funding Opportunities instead). Investigators strongly encouraged discuss research plans NCCIH program staff prior submitting application. NICHD: Characterization the cannabinoids endocannabinoid system potential targets treatment dysmenorrhea, vulvodynia, chronic pelvic pain due endometriosis other gynecologic disorders. Studies the role these systems the management spasticity, neuropathic pain, bone pain, musculoskeletal pain pain secondary other disabling conditions. Cannabinoids endocannabinoid system their therapeutic adverse effects pregnancy its outcomes. NIAAA: Alcohol abuse/dependence causes increased pain sensitivity neuropathic pain. role endocannabinoids mediating actions alcohol inducing regulating pain responses be primary interest. Modified Read: Part 1. Overview Information Components Participating Organizations National Institute Drug Abuse NIDA) National Cancer Institute NCI)) National Center Complementary Integrative Health NCCIH) National Institute Alcohol Abuse Alcoholism NIAAA) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Aging NIA) National Institute Neurological Disorders Stroke NINDS) Catalog Federal Domestic Assistance CFDA) Number(s) 93.279, 93.393, 93.213, 93.273, 93.853, 93.865, 93.866 Part 2. Full Text Announcement Section I. Funding Opportunity Description addition the topics listed above, additional specific areas interest some the participating ICs outlined below. Applicants encouraged contact participating IC's Scientific/Research contact discuss submission gauge interest the participating institute. NIDA: Examine role various combinations potencies the main cannabinoids THC CBD) their effects modulating endocannabinoid system pain perception analgesia; effects long-term endocannabinoid system therapies addiction liability. NCI: role cannabinoids the endocannabinoid system the treatment tumor-related pain conditions, such metastatic bone pain, painful conditions arising the treatment cancer, such chemotherapy induced peripheral neuropathy, aromatase inhibitor arthralgias, radiation induced stomatitis. NCCIH: role naturally occurring phytocannabinoids their derivatives either alone in conjunction other complementary approaches e.g. natural products, mind-body programs) modulating biological neural systems associated pain perception analgesia relevant model organisms human subjects well the mechanisms underlying cannabinoid analgesic anti-inflammatory properties. NCCIH not fund research proposing efficacy effectiveness clinical trials through FOA please NCCIH Clinical Trial Funding Opportunities instead). Investigators strongly encouraged discuss research plans NCCIH program staff prior submitting application. NICHD: Characterization the cannabinoids endocannabinoid system potential targets treatment dysmenorrhea, vulvodynia, chronic pelvic pain due endometriosis other gynecologic disorders. Studies the role these systems the management spasticity, neuropathic pain, bone pain, musculoskeletal pain pain secondary other disabling conditions. Cannabinoids endocannabinoid system their therapeutic adverse effects pregnancy its outcomes. NINDS: Interest exclusively focused the effect the endogenous cannabinoid system the neural mechanisms pain the transition acute chronic pain. NIAAA: Alcohol abuse/dependence causes increased pain sensitivity neuropathic pain. role endocannabinoids mediating actions alcohol inducing regulating pain responses be primary interest. other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Michael Oshinsky, PhD National Institute Neurological Disorders & Stroke NINDS) Telephone: 301-496-9964 Email:michael.oshinsky@nih.gov

Notice Change the Data Safety Monitoring Plan PAR-18-422 NINDS Efficacy Clinical Trials U01 Clinical Trial Required) Notice Number: NOT-NS-20-013 Key Dates Release Date: January 03, 2020 Related Announcements PAR-18-422 Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this Notice to update instructions regarding Data Safety Monitoring Plan PAR-18-422. Currently reads: 3.3 Data Safety Monitoring Plan Applicants should refer the NINDS Guidelines Data Safety Monitoring Clinical Trials https://www.ninds.nih.gov/Funding/Apply-Funding/Application-Support-Lib…) developing DSMP. Modified read: 3.3 Data Safety Monitoring Plan Applicants should refer the NINDS Guidelines Data Safety Monitoring Clinical Trials https://www.ninds.nih.gov/Funding/Apply-Funding/Application-Support-Lib…) developing DSMP. Note these guidelines been updated include requirement an independent statistician report unblinded study analyses the Data Safety Monitoring Board. other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Peter Gilbert, ScM National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-0870 Email: pgilbert@nih.gov

Notice Intent Publish Funding Opportunity Announcement HEAL Initiative: Pain Management Effectiveness Research Network: Clinical Trial Planning Implementation Cooperative Agreement UG3/UH3 Clinical Trial Required) Notice Number: NOT-NS-20-020 Key Dates Release Date: December 26, 2019 Estimated Publication Date Funding Opportunity Announcement: January 20, 2020 First Estimated Application Due Date: March 24, 2020 Earliest Estimated Award Date: August 31, 2020 Earliest Estimated Start Date: August 31, 2020 Related Announcements None Issued National Institute Neurological Disorders Stroke ( NINDS) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Dental Craniofacial Research NIDCR) National Institute Drug Abuse NIDA) National Institute Nursing Research NINR) National Institute Minority Health Health Disparities NIMHD) National Center Complementary Integrative Health NCCIH) National Center Advancing Translational Sciences NCATS) National Cancer Institute NCI) Purpose purpose this Notice to inform potential applicants the National Institute Neurological Disorders Stroke NINDS) intends publish re-issuance funding opportunity announcement RFA-NS-19-021 solicit applications clinical trial planning implementation generate evidence-based pain management best practices the of existing medications devices specific pain conditions. Notice being provided allow potential applicants sufficient time develop meaningful collaborations responsive projects. funding opportunity announcement expected be published December 2019 an expected application due date March 2020. Applicant organizations submit than application, provided application proposes distinct clinical trial. funding opportunity announcement utilize UG3/UH3 bi-phasic activity code. Research Initiative Details Most chronic pain management delivered the primary care settings where providers few evidence-based guidelines support clinical decisions. Acute pain management often delivered emergency departments, hospital settings dental clinics where reliance treatment opioids increases risks Opioid Disorder OUD). Adults pain due injury, neck back pain, abdominal pain headache up over 33 million ER visits per year. . Evidence best pain care practices these settings lacking, only acute pain relief, also prevention chronic pain OUD. addition, quality, precision pain care following surgical other procedures medications including opioids other pharmacological therapies devices provide more robust evidence base guide providers these settings, promote tailored acute pain care, reduce reliance opioids. re-release HEAL Initiative: Pain Management Effectiveness Research Network: Clinical Trial Planning Implementation Cooperative Agreement UG3/UH3 Clinical Trial Required) prioritize following areas interest generate evidence-based pain management best practices the of existing medications devices specific pain conditions. guidelines should of to providers primary care, emergency departments, dental clinics, hospital settings. pain conditions high priority are: pain management emergency departments, dental clinics, primary care hospitals; chronic overlapping pain conditions; best practices effective analgesics appropriate; pain management individuals risk or OUD; pain management those co-occurring mental health disorders; Non cancer pain management persons medical comorbidities Research testing behavioral interventions manage pain not considered high priority projects since several currently funded HEAL trials testing behavioral interventions pain management. Investigators wishing test effectiveness behavioral interventions should contact program officials individual ICs find appropriate FOA. Research testing software decision-making tools help providers patients determine most effective safe methods pharmacological device pain management allowed. Funding Information Estimated Total Funding 800,000 total costs FY2020; 2,000,000 total costs per year FY2021, FY2022, FY2023, FY2024 Expected Number Awards to 2. Estimated Award Ceiling to 500,000 direct cost the one-year UG3 phase up 1,000,000 per year direct cost the UH3 phase no than 4 years. Note the Trial Innovation Network provide infrastructure including data management system, clinical coordination, support trial document development such the manual procedures. costs should be included the UG3/UH3 budgets. Primary CFDA Numbers 93.853 Anticipated Eligible Organizations Public/State Controlled Institution Higher Education Private Institution Higher Education Nonprofit 501(c)(3) IRS Status than Institution Higher Education) Small Business For-Profit Organization than Small Business) State Government Indian/Native American Tribal Government Federally Recognized) County governments Independent school districts Public housing authorities/Indian housing authorities Indian/Native American Tribally Designated Organization Native American tribal organizations than Federally recognized tribal governments) U.S. Territory Possession Indian/Native American Tribal Government than Federally Recognized) Non-domestic non-U.S.) Entity Foreign Organization) Regional Organization Applications not being solicited this time. Inquiries Please direct inquiries to: Linda L. Porter, Ph.D. National Institute Neurological Disorders Stroke NINDS) 301-435-7572 porterl@ninds.nih.gov Jane C. Atkinson, DDS National Center Advancing Translational Sciences NCATS) Telephone: 301-827-6031 Email: jatkinso@mail.nih.gov

Notice Extend Expiration Date PA-18-141 Mechanisms, Models, Measurement, & Management Pain Research R01 Clinical Trial Optional)" Notice Number: NOT-NS-20-021 Key Dates Release Date: December 18, 2019 Related Announcements PA-18-141 Issued National Institute Neurological Disorders Stroke NINDS) National Institute Aging NIA) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Dental Craniofacial Research NIDCR) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Drug Abuse NIDA) National Institute Nursing Research NINR) National Institute Minority Health Health Disparities NIMHD) National Center Complementary Integrative Health NCCIH) National Cancer Institute NCI) Purpose purpose this notice to inform interested applicants a change the Key Dates PA-18-141 ""Mechanisms, Models, Measurement, & Management Pain Research R01 Clinical Trial Optional)". Four additional receipt dates been added changes shown bold italics below). Funding Opportunity Announcement been modified add following New Application due dates: February 5, 2020, June 5, 2020, October 5, 2020, February 5, 2021 new applications) March 5, 2020, July 5, 2020, November 5, 2020, and March 5, 2021 (renewal, resubmission, revision applications) AIDS Application Due Dates of May 7, 2020, September 7, 2020, January 7, 2021, and May 7, 2021. Currently Reads: Part 1. Overview Key Dates: Application Due Date(s) Standard dates , 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. AIDS Application Due Date(s) Standard AIDS dates apply, 5:00 PM local time applicant organization. All types AIDS AIDS-related applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review Standard dates apply Advisory Council Review Standard dates apply Earliest Start Date Standard dates apply Expiration Date January 8, 2020 Modified Read: Part 1. Overview Key Dates: Application Due Date(s) Standard dates , 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. AIDS Application Due Date(s) Standard AIDS dates apply, 5:00 PM local time applicant organization. Alltypes AIDS AIDS-related applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review Standard dates apply Advisory Council Review Standard dates apply Earliest Start Date Standard dates apply Expiration Date 8, 2021 other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Michael Oshinsky, PhD National Institute Neurological Disorders & Stroke NINDS) Telephone: 301-496-9964 Email:michael.oshinsky@nih.gov Martha Matocha, PhD National Institute Nursing Research NINR) Telephone: 301-594-2775 Email: matocham@mail.nih.gov

Notice Extend Expiration Date PA-18-159 Mechanisms, Models, Measurement, amp; Management Pain Research R21 Clinical Trial Optional)" Notice Number: NOT-NS-20-022 Key Dates Release Date: December 18, 2019 Related Announcements PA-18-159 Issued National Institute Neurological Disorders Stroke NINDS) National Institute Aging NIA) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Dental Craniofacial Research NIDCR) National Institute Drug Abuse NIDA) National Institute Nursing Research NINR) National Institute Minority Health Health Disparities NIMHD) National Center Complementary Integrative Health NCCIH) National Cancer Institute NCI) Purpose purpose this notice to inform interested applicants a change the Key Dates PA-18-159 ""Mechanisms, Models, Measurement, amp; Management Pain Research R21 Clinical Trial Optional)". Four additional receipt dates been added changes shown bold italics below). Funding Opportunity Announcement been modified add following New Application due dates: February 16, 2020, June 16, 2020, October 16, 2020, February 16, 2021 (new applications) and March 16, 2020, July 16, 2020, November 16, 2020, and March 16, 2021 (renewal, resubmission, revision applications) AIDS Application Due Dates of May 7, 2020, September 7, 2020, January 7, 2021, and May 7, 2021. Additionally, effective immediately, NIAMS no longer participating PA-18-159 will accept applications response PA-18-159. Currently Reads: Part 1. Overview Components Participating Organizations National Cancer Institute NCI) National Institute Nursing Research NINR) National Institute Aging NIA) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Drug Abuse NIDA) National Institute Dental Craniofacial Research NIDCR) National Institute Neurological Disorders Stroke NINDS) National Center Complementary Integrative Health NCCIH) National Institute Minority Health Health Disparities NIMHD) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) Catalog Federal Domestic Assistance CFDA) Number(s) 93.361; 93.866; 93.846; 93.279; 93.121; 93.853; 93.213; 93.307; 93.393, 93.865 Key Dates: Application Due Date(s) Standard dates apply, 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. AIDS Application Due Date(s) Standard AIDS dates apply, 5:00 PM local time applicant organization. All types AIDS AIDS-related applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review Standard dates apply Advisory Council Review Standard dates apply Earliest Start Date Standard dates apply Expiration Date January 8, 2020 Modified Read: Part 1. Overview Components Participating Organizations National Cancer Institute NCI) National Institute Nursing Research NINR) National Institute Aging NIA) National Institute Drug Abuse NIDA) National Institute Dental Craniofacial Research NIDCR) National Institute Neurological Disorders Stroke NINDS) National Center Complementary Integrative Health NCCIH) National Institute Minority Health Health Disparities NIMHD) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) Catalog Federal Domestic Assistance CFDA) Number(s) 93.361; 93.866; 93.279; 93.121; 93.853; 93.213; 93.307; 93.393, 93.865 Key Dates: Application Due Date(s) Standard dates apply, 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. AIDS Application Due Date(s) Standard AIDS dates apply, 5:00 PM local time applicant organization. All types AIDS AIDS-related applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review Standard dates apply Advisory Council Review Standard dates apply Earliest Start Date Standard dates apply Expiration Date 8, 2021 other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Michael Oshinsky, PhD National Institute Neurological Disorders amp; Stroke NINDS) Telephone: 301-496-9964 Email:michael.oshinsky@nih.gov Martha Matocha, PhD National Institute Nursing Research NINR) Telephone: 301-594-2775 Email: matocham@mail.nih.gov

Request Information: Curing Epilepsies 2020: Setting Research Priorities Notice Number: NOT-NS-20-025 Key Dates Release Date: December 13, 2019 Response Date: February 20, 2020 Related Announcements None Issued National Institute Neurological Disorders Stroke NINDS ) Purpose purpose this Request Information RFI) to seek broad input scientists, clinicians, patients, families, caregivers, advocates, the broader epilepsy community the most important new ongoing challenges opportunities epilepsy research. Input be considered updating 2014 Epilepsy Research Benchmarks setting Epilepsy Research Priorities the Curing Epilepsies 2020 Conference. Background Since 2000, NINDS worked the epilepsy community identify priorities research. 2000, 2007 2013, NINDS sponsored Curing Epilepsy conferences partnership nongovernmental organizations other Federal agencies assess state epilepsy research identify needs new directions. conferences led the development subsequent revisions the Epilepsy Research Benchmarks, series goals research toward cures the epilepsies, defined no seizures, side effects, the prevention epilepsy those risk. Since initial development 2000, Benchmarks brought attention goals such preventing epileptogenesis, addressing aspects epilepsy beyond seizures, confronting challenge sudden unexpected death epilepsy SUDEP). Benchmarks meant engage entire epilepsy community advancing research, including NIH, NIH grantees other researchers, epilepsy professional organizations, the epilepsy patient community. NINDS particular considers Benchmarks planning new investments epilepsy research has also worked epilepsy researchers serve Benchmarks Stewards track promote progress. The ICARE Epilepsy Research Portfolio tracks research funding towards benchmarks the federal nonprofit members the Interagency Collaborative Advance Research Epilepsy ICARE). April 13-15, 2020, NINDS sponsor fourth public conference, Curing Epilepsies 2020: Setting Research Priorities" reassess state epilepsy research. conference include scientific sessions major topics the field will culminate a discussion possible updates the Epilepsy Research Benchmarks. new goal the conference be each benchmark area develop several key gap priorities address research areas needing substantial focused effort order make significant advances. gap priorities focus areas where is currently limited research knowledge and/or where collaborative community efforts make significant scientific progress the next 5-7 years toward cures the epilepsies. information submitted response this RFI be used the benchmark stewards committee revise update the 2014 Epilepsy Research Benchmarks. draft revisions the benchmarks recommended gap priorities be presented the public further input the Curing Epilepsies 2020 conference, will take place April 13-15, 2020, the main NIH campus Bethesda, MD Register attend at Curing Epilepsies 2020. Registration free open the public). Information Requested NINDS soliciting input all interested stakeholders, including researchers, health care providers, individuals epilepsy, patient advocates health advocacy organizations, scientific professional organizations, federal agencies, well other interested members the public. Organizations strongly encouraged submit single response reflects views their organization membership a whole. Please provide perspectives the following topics: Comments suggestions regarding current 2014 epilepsy research benchmarks -- examples include comments benchmarks could removed because have achieved and/or no longer priorities, the current benchmarks be revised, any new research questions should included, based scientific progress since 2013. New ongoing research priority challenges opportunities. Identify most promising areas research the community should focus concerted efforts based knowledge gaps research needs, which significantly advanced the next 5-7 years. priorities should areas epilepsy research require concerted coordinated effort will transform significantly advance research the area. to Submit Response assure consideration, responses must received February 20, 2020, should submitted electronically.  Responses voluntary may submitted anonymously. Respondents advised the Government under obligation acknowledge receipt the information received provide feedback respondents respect any information submitted. Responses be shared publicly the Curing Epilepsies 2020 conference. Please not include any personally identifiable other information you not wish make public. proprietary, classified, confidential, sensitive information should included your response. request for planning purposes only should be construed a solicitation as obligation the part the United States Government. NIH not any awards based responses this RFI pay the preparation any information submitted for Government's of such information. Inquiries Please direct inquiries to: Miriam Leenders, PhDNational Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1917 Email: miriam.leenders@nih.gov

Notice Extension the Response Date NOT-NS-19-080 Solicitation Nominations the 2020 National Institute Neurological Disorders Stroke NINDS) Landis Award Outstanding Mentorship" Notice Number: NOT-NS-20-028 Key Dates Release Date: December 3, 2019 Related Announcements NOT-NS-19-080 Issued National Institute Neurological Disorders Stroke NINDS) Purpose notice extends response date NOT-NS-19-080 Solicitation Nominations the 2020 National Institute Neurological Disorders Stroke NINDS) Landis Award Outstanding Mentorship." following sections NOT-NS-19-080 been updated: Key Dates Current Response Date: December 01, 2019 New Response Date: December 15, 2019 other aspects the RFI remain same. Inquiries Please direct inquiries to: Stephen Korn, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-4188 Email: korns@ninds.nih.gov